Status: Recruiting
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SIF001 in Healthy Subjects and in Epilepsy Patients
This is a dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of SIF001, a monoclonal antibody with the potential to treat epilespy
Participants needed: 88
Trial details
Phase: Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: Suninflam IncUpdated: Jun 15, 2026Locations: 10
Eligibility criteria
Male or female 18 to 55 years of age at the time of signing the informed consent... [+9]
Subjects with any unresolved history of clinically significant disease, in the o... [+18]